BTLA and systemic inflammatory response syndrome: Further, these data illustrate the value of BTLA as a potential therapeutic target and a possible biomarker for identifying the critically ill patients whom are most susceptible to develop subsequent or secondary infections, and thereby may allow for the delivery of the sufficient therapies that are needed to help prevent the morbidity and mortality associated with SIRS and sepsis.